{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:06:51Z","timestamp":1794712011001,"version":"4.9.1"},"reference-count":70,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemias (AML) containing TP53 (p53) mutations are routinely treated with decitabine or 5-azacytidine, which deplete DNA methyltransferase 1 (DNMT1; ie, hypomethylating agents [HMA]). Unfortunately, resistance\/relapse, characterized by preserved DNMT1, is rapid. HMA are pyrimidine analogs, and to deplete DNMT1, must compete with endogenous pyrimidines. These were substantially increased in HMA-resistant vs parental AML cells, together with upregulation of CAD (carbamoyl-phosphate-synthetase-2\/aspartate transcarbamylase\/dihydroorotase) that rate limits de novo pyrimidine synthesis. Moreover, TP53-mutated AML appeared primed for such resistance, with higher baseline CAD. Pyrimidine synthesis can be depowered with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax to release BCL-2\u2013associated X protein (BAX) to depolarize mitochondrial membranes. However, BAX, a p53 target gene, was substantially less expressed in TP53-mutated vs wild-type TP53 cells, and venetoclax impacts were correspondingly limited. Alternatively, pyrimidine synthesis can be inhibited directly at dihydroorotate dehydrogenase (DHODH) using the clinical drug teriflunomide. Contrasting with venetoclax, teriflunomide decreased pyrimidine levels several-fold, restored DNMT1 depletion, and cytoreduced HMA-resistant TP53-mutated AML cells via p53\/apoptosis-independent terminal-differentiation. This noncytotoxic pathway preserved viability and proliferation of normal hematopoietic stem\/progenitor cells (NHSPCs). Inhibiting pyrimidine synthesis triggered compensatory pyrimidine salvage, such that schedules for teriflunomide combination with HMA, which are taken up by salvage, mattered. In mice with TP53-mutated AML, teriflunomide scheduled the day before HMA was more efficacious than same-day or day-after schedules. Chronic teriflunomide exposure paradoxically increased pyrimidines via sustained compensatory salvage, conferring resistance rather than sensitivity to HMA. In sum, DNMT1 and DHODH targeting, administered by timed, intermittent (metronomic) schedules, can circumvent genetic resistance caused by TP53 mutations and adaptive resistance caused by metabolic homeostasis, without cytotoxicity to HSPCs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016683","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:53:46Z","timestamp":1759953226000},"page":"6410-6424","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Combining drugs that bypass p53 to treat\n                    <i>TP53<\/i>\n                    -mutated leukemias"],"prefix":"10.1182","volume":"9","author":[{"given":"Sudipta","family":"Biswas","sequence":"first","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Albadry M.","family":"Zahran","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"},{"name":"2Department of Clinical Pathology, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Gu","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cardone","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remuna","family":"Marti","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Mouannes","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-9058","authenticated-orcid":false,"given":"Maximilian","family":"Stich","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics I, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Jain","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Fedorov","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Vanderbilt University, Tennessee, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-0973","authenticated-orcid":false,"given":"Benjamin","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, University Hospitals, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Oncology, Albert Einstein Medical School, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Oncology, Albert Einstein Medical School, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-1031","authenticated-orcid":false,"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[{"name":"1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"},{"name":"4Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"11","key":"2025122309461066500_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"2025122309461066500_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/hematology.2024000557","article-title":"Nontransplant treatment approaches for myeloid neoplasm with mutated TP53","volume":"2024","author":"Mehta","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2025122309461066500_bib3","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2025122309461066500_bib4","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies","volume":"84","author":"Wattel","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2025122309461066500_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/leu.2011.159","article-title":"p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia","volume":"25","author":"Ng","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2025122309461066500_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2025122309461066500_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1172\/JCI78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"2025122309461066500_bib8","doi-asserted-by":"crossref","first-page":"113016","DOI":"10.1016\/j.celrep.2023.113016","article-title":"Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy","volume":"42","author":"Biswas","year":"2023","journal-title":"Cell Rep"},{"issue":"21","key":"2025122309461066500_bib9","doi-asserted-by":"crossref","first-page":"14881","DOI":"10.1074\/jbc.M114.562447","article-title":"Runx1 regulation of Pu.1 corepressor\/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy","volume":"289","author":"Gu","year":"2014","journal-title":"J Biol Chem"},{"issue":"10","key":"2025122309461066500_bib10","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J Clin Invest"},{"issue":"12","key":"2025122309461066500_bib11","doi-asserted-by":"crossref","first-page":"109747","DOI":"10.1016\/j.celrep.2021.109747","article-title":"PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation","volume":"36","author":"Gu","year":"2021","journal-title":"Cell Rep"},{"issue":"38","key":"2025122309461066500_bib12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/EDBK_199753","article-title":"Ultimate precision: targeting cancer but not normal self-replication","volume":"38","author":"Velcheti","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"24","key":"2025122309461066500_bib13","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025122309461066500_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2025122309461066500_bib15","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2025122309461066500_bib16","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2025122309461066500_bib17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3324\/haematol.2021.280153","article-title":"Decitabine salvage for TP53-mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","volume":"107","author":"Ferraro","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2025122309461066500_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025122309461066500_bib19","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2025122309461066500_bib20","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025122309461066500_bib21","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/bloodadvances.2022008747","article-title":"An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first International Workshop in MDS","volume":"7","author":"Stahl","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2025122309461066500_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2025122309461066500_bib23","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1038\/s41375-020-0973-z","article-title":"Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia","volume":"34","author":"Gruber","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025122309461066500_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2020.11.008","article-title":"A pilot clinical trial of oral tetrahydrouridine\/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies","volume":"58","author":"Hill","year":"2021","journal-title":"Semin Hematol"},{"issue":"13","key":"2025122309461066500_bib25","doi-asserted-by":"crossref","first-page":"11132","DOI":"10.1074\/jbc.M110.202283","article-title":"Deoxyribonucleotide metabolism in cycling and resting human fibroblasts with a missense mutation in p53R2, a subunit of ribonucleotide reductase","volume":"286","author":"Pontarin","year":"2011","journal-title":"J Biol Chem"},{"issue":"16","key":"2025122309461066500_bib26","doi-asserted-by":"crossref","first-page":"e2503531122","DOI":"10.1073\/pnas.2503531122","article-title":"RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis","volume":"122","author":"Awoyomi","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025122309461066500_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mrgentox.2010.06.002","article-title":"Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances","volume":"703","author":"Rampazzo","year":"2010","journal-title":"Mutat Res"},{"issue":"9","key":"2025122309461066500_bib28","doi-asserted-by":"crossref","first-page":"e1002382","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med"},{"issue":"3","key":"2025122309461066500_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ejh.14009","article-title":"Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine","volume":"111","author":"Lau","year":"2023","journal-title":"Eur J Haematol"},{"issue":"19","key":"2025122309461066500_bib30","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood.2024025761","article-title":"GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia","volume":"145","author":"Alikarami","year":"2025","journal-title":"Blood"},{"key":"2025122309461066500_bib31","doi-asserted-by":"crossref","first-page":"678008","DOI":"10.3389\/fonc.2021.678008","article-title":"Cellular metabolomics profiles associated with drug chemosensitivity in AML","volume":"11","author":"Stockard","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"2025122309461066500_bib32","doi-asserted-by":"crossref","first-page":"e184021","DOI":"10.1172\/JCI184021","article-title":"TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment","volume":"135","author":"Zhang","year":"2025","journal-title":"J Clin Invest"},{"issue":"7728","key":"2025122309461066500_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"12","key":"2025122309461066500_bib34","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2025122309461066500_bib35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2025122309461066500_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.10.043","article-title":"A global map of p53 transcription-factor binding sites in the human genome","volume":"124","author":"Wei","year":"2006","journal-title":"Cell"},{"issue":"10","key":"2025122309461066500_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.18632\/oncotarget.597","article-title":"High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects","volume":"3","author":"Ebrahem","year":"2012","journal-title":"Oncotarget"},{"issue":"6","key":"2025122309461066500_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjh.16281","article-title":"Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies","volume":"188","author":"Awada","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"2025122309461066500_bib39","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/ccr3.1221","article-title":"Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen","volume":"5","author":"Saleh","year":"2017","journal-title":"Clin Case Rep"},{"issue":"15","key":"2025122309461066500_bib40","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","article-title":"A metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2025122309461066500_bib41","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2024025834","article-title":"A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort","volume":"144","author":"Goldfinger","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025122309461066500_bib42","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2 '-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2025122309461066500_bib43","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2011-03-341909","article-title":"A pilot study of subcutaneous decitabine in beta-thalassemia intermedia","volume":"118","author":"Olivieri","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025122309461066500_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ijc.26320","article-title":"Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo","volume":"131","author":"Alcazar","year":"2012","journal-title":"Int J Cancer"},{"issue":"9","key":"2025122309461066500_bib45","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00262-012-1204-x","article-title":"Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice","volume":"61","author":"Triozzi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"41","key":"2025122309461066500_bib46","doi-asserted-by":"crossref","first-page":"69906","DOI":"10.18632\/oncotarget.19436","article-title":"Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells","volume":"8","author":"Imanishi","year":"2017","journal-title":"Oncotarget"},{"key":"2025122309461066500_bib47","doi-asserted-by":"crossref","first-page":"100805","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"\u0160imoni\u010dov\u00e1","year":"2022","journal-title":"Drug Resist Updat"},{"issue":"3","key":"2025122309461066500_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/mol.62.3.463","article-title":"A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools","volume":"62","author":"Huang","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"8","key":"2025122309461066500_bib49","doi-asserted-by":"crossref","first-page":"e179788","DOI":"10.1172\/JCI179788","article-title":"Oncotherapy resistance explained by Darwinian and Lamarckian models","volume":"134","author":"Saunthararajah","year":"2024","journal-title":"J Clin Invest"},{"issue":"9","key":"2025122309461066500_bib50","doi-asserted-by":"crossref","first-page":"e04533","DOI":"10.1002\/ccr3.4533","article-title":"A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia","volume":"9","author":"Zawit","year":"2021","journal-title":"Clin Case Rep"},{"issue":"2","key":"2025122309461066500_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428194.2013.802315","article-title":"Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine","volume":"55","author":"Liu","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025122309461066500_bib52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/10428194.2014.916805","article-title":"Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts","volume":"56","author":"Tabarroki","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025122309461066500_bib53","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025122309461066500_bib54","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2025122309461066500_bib55","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025122309461066500_bib56","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","article-title":"Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia","volume":"107","author":"Cojocari","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2025122309461066500_bib57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers14010248","article-title":"Epigenetic priming with decitabine augments the therapeutic effect of cisplatin on triple-negative breast cancer cells through induction of proapoptotic factor NOXA","volume":"14","author":"Nakajima","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025122309461066500_bib58","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2141.2007.06707.x","article-title":"Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition","volume":"138","author":"Choi","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122309461066500_bib59","first-page":"101","article-title":"Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816)","volume":"27","author":"Lomen","year":"1980","journal-title":"Neoplasma"},{"issue":"12","key":"2025122309461066500_bib60","first-page":"4610","article-title":"Pyrazofurin enhancement of 5-azacytidine antitumor activity in L5178Y and human leukemia cells","volume":"38","author":"Cadman","year":"1978","journal-title":"Cancer Res"},{"issue":"3-4","key":"2025122309461066500_bib61","first-page":"237","article-title":"Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia","volume":"65","author":"Martelo","year":"1981","journal-title":"Cancer Treat Rep"},{"issue":"12 pt 1","key":"2025122309461066500_bib62","first-page":"5505","article-title":"Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis","volume":"44","author":"Grant","year":"1984","journal-title":"Cancer Res"},{"key":"2025122309461066500_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4615-2488-5_13","article-title":"Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate","volume":"339","author":"Grem","year":"1993","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"2025122309461066500_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/bloodadvances.2020001461","article-title":"DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes","volume":"5","author":"Kayamori","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2025122309461066500_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1097-0142(19890115)63:2<243::AID-CNCR2820630207>3.0.CO;2-7","article-title":"Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis","volume":"63","author":"Schwartsmann","year":"1989","journal-title":"Cancer"},{"issue":"5","key":"2025122309461066500_bib66","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers13051003","article-title":"The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia","volume":"13","author":"Gaidano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"2025122309461066500_bib67","doi-asserted-by":"crossref","first-page":"e18592","DOI":"10.1111\/jcmm.18592","article-title":"Single low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage","volume":"28","author":"Jitaru","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"11","key":"2025122309461066500_bib68","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2003-07-2431","article-title":"Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A","volume":"103","author":"Milhem","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2025122309461066500_bib69","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/1535-7163.MCT-10-0191","article-title":"Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus","volume":"9","author":"Hu","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"1-2","key":"2025122309461066500_bib70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.10.003","article-title":"The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro","volume":"265","author":"Li","year":"2013","journal-title":"J Neuroimmunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6410\/2476882\/blooda_adv-2025-016683-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6410\/2476882\/blooda_adv-2025-016683-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:46:23Z","timestamp":1766501183000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6410\/547645\/Combining-drugs-that-bypass-p53-to-treat-TP53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":70,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016683","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}